uric acid has been researched along with Hyperphosphatemia in 7 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Early markers of CVD such as microalbuminuria and uric acid levels need to be added to the routine annual evaluation, particularly among high-risk individuals such as diabetics, hypertensives, smokers, and the elderly." | 4.85 | Chronic kidney disease: a marker of cardiovascular disease. ( Nguyen, PT; Olivero, JJ, 2009) |
| "Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function." | 3.81 | Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. ( Prasada, H, 2015) |
| "Long-term flexible dosing with colestilan reduces serum phosphorus and demonstrates an acceptable safety and tolerability profile." | 2.82 | Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia. ( Dimkovic, N; Locatelli, F; Spasovski, G; Wanner, C, 2016) |
| "Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders." | 2.77 | Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. ( Ahmadi, F; Khatami, MR; Lessan-Pezeshki, M; Shamekhi, F, 2012) |
| "Hyperphosphatemia is a major problem in these patients especially at advanced stages of CKD, and it is associated with cardiovascular and mineral complications in these patients." | 2.50 | [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent]. ( Maizel, J; Massy, ZA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenglet, A | 1 |
| Fabresse, N | 1 |
| Taupin, M | 1 |
| Gomila, C | 1 |
| Liabeuf, S | 1 |
| Kamel, S | 1 |
| Alvarez, JC | 1 |
| Drueke, TB | 1 |
| Massy, ZA | 2 |
| Alam, S | 1 |
| Hussain, A | 1 |
| Daiwajna, R | 1 |
| Tan, J | 1 |
| Maizel, J | 1 |
| Prasada, H | 1 |
| Locatelli, F | 1 |
| Spasovski, G | 1 |
| Dimkovic, N | 1 |
| Wanner, C | 1 |
| Olivero, JJ | 2 |
| Nguyen, PT | 1 |
| Ahmadi, F | 1 |
| Shamekhi, F | 1 |
| Lessan-Pezeshki, M | 1 |
| Khatami, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia[NCT00772382] | Phase 3 | 116 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00772382)
Timeframe: 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| MCI-196 | -1.18 |
(NCT00772382)
Timeframe: 52 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| At least 1 treatment-emergent AE | At least 1 drug-related treatment-emergent AE | At least 1 treatment-emergent serious AE | |
| MCI-196 | 109 | 50 | 63 |
2 reviews available for uric acid and Hyperphosphatemia
| Article | Year |
|---|---|
[Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
Topics: Animals; Bone Remodeling; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Disease Mode | 2014 |
Chronic kidney disease: a marker of cardiovascular disease.
Topics: Albuminuria; Anemia; Biomarkers; Blood Urea Nitrogen; Cardiovascular Diseases; Creatinine; Glomerula | 2009 |
3 trials available for uric acid and Hyperphosphatemia
| Article | Year |
|---|---|
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
Topics: Aged; Endotoxemia; Endotoxins; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Human | 2019 |
Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
Topics: Adult; Aged; Bile Acids and Salts; Cholesterol, LDL; Diarrhea; Female; Glycated Hemoglobin; Hemodial | 2016 |
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Calcium; Chelating Agents; Female; Humans; Hyperphosp | 2012 |
2 other studies available for uric acid and Hyperphosphatemia
| Article | Year |
|---|---|
Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study.
Topics: Adult; Bone Diseases; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Fai | 2013 |
Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
Topics: Child; Humans; Hyperphosphatemia; Male; Phosphates; Sevelamer; Tumor Lysis Syndrome; Uric Acid | 2015 |